Dr. Peter Schlegel, Chairman of Weill Cornell Medicine Urology, was featured on a National Geographic segment regarding male fertility.
In this clip, Dr. Schlegel discusses average sperm counts for men currently, and how this figure may have changed in recent decades. Dr. Schlegel's lab analyzes a semen sample from a patient, to show the appearance and quantity of sperm in the patient's sample.
The New York Times reported on various responses to a recent study suggesting that sperm counts have been dropping for decades. Dr. Peter Schlegel, Chairman of Weill Cornell Urology, is featured for commentary, noting that male infertility is not rising at an alarming rate.
Please join us in congratulating Dr. Marc Goldstein for receiving the 2018 Distinguished Reproductive Urology Award from the Society for the Study of Male Reproduction (SSMR). Dr. Goldstein was presented with this prestigious award during the 2018 AUA Annual Meeting in San Francisco. This award was given in recognition of Dr. Goldstein's significant contributions in the field of reproductive urology and his service to the SSMR. To learn more about Dr.
Marc Goldstein, MD, is fond of saying, "I have a son and two granddaughters, but every time I get a call that one of my couples who I've treated is pregnant, it feels to me like it's one of my own. So, when anyone asks how many children I have, I tell them I have 5,000!"
On January 29, 2018, The Department of Urology hosted a symposium for patients on the newest treatment approaches for severe male infertility. This includes men with no sperm in the ejaculate (azoospermia) because of low sperm production as well as men with this condition of non-obstructive azoospermia that have failed attempts at testicular sperm retrieval (detection & removal of sperm from the testicle using microTESE.)
Dr. Peter Schlegel, Chairman of Urology at Weill Cornell Medicine, was featured in Newsweek, discussing the potential for a male birth control pill that would temporarily stop sperm production. Dr. Schlegel comments on recent research that lays a "genetic foundation for male birth control" in an animal study. He also explains some of the biological barriers that make the development of a male birth control pill a complex task:
Marc Goldstein, MD, DSc (hon), FACS discusses his role as a urologist, surgeon and pioneer in male infertility evaluation and treatment at Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York City. To make an appointment with Dr. Goldstein in NYC, please call his office at (212) 746-5470. For more information on Dr. Goldstein, please visit: http://urology.weillcornell.org/marc-goldstein
A fertility evaluation is often pursued in couples who have not been able to conceive for a period of 6-12 months of unprotected intercourse. A fertility evaluation may be appropriate sooner than this when the couple is considered to be at higher risk for subfertility or infertility: when the female partner is over age 35; when there has been a history of infertility in a prior relationship; or when there are other risk factors which may cause fertility problems (e.g. cryptorchidism, testicular neoplasm, chemotherapy, radiation therapy).
The human male reproductive system includes hormonal and structural components. These components include the hypothalamic-pituitary-testis axis as well as the epididymis, vas deferens, seminal vesicles, prostate and urethra. Production of spermatozoa requires approximately 3 months from the initial duplication of stem cells that are supposed to develop into sperm, through mitotic divisions and the myriad changes that modify sperm, preparing them for ejaculation and fertilization.